Caso contributivo
Sindrome di Alpers-Huttenlocher, epilessia, uso del perampanel e medicina narrativa
Alpers-Huttenlocher syndrome, epilepsy, use of perampanel and narrative medicine
Paolo Ricciardelli1, Andrea Zucchini1, Maria Francesca Gatto2, Giovanna Rametta3, Federico Marchetti1
1UOC di Pediatria e Neonatologia; 2Servizio di Neurofisiologia; 3Servizio di Farmacia Ospedaliera
Presidi Ospedalieri di Ravenna e Faenza, AUSL della Romagna
Novembre 2017
Abstract
Alpers-Huttenlocher Syndrome (AHS) is a mitochondrial disease that should be suspected in the presence of three clinical cases: refractory epilepsy, liver disease and pro-gressive psychomotor regression. The onset occurs within the first year of age or in the early childhood. In some cases liver disease may precede the onset of seizures and psychomotor regression, while in more rare cases it may be absent or have a tardive onset.
Unfortunately, the prognosis of the syndrome is not fa-vourable as it may develop into a difficult-to-treat en-cephalopathy whose features are spasticity, myoclonias, and focal epilepsy with possible status epilepcticus.
The paper describes the case of a girl aged 3 years and ten months with genetic diagnosis of AHS, with no hepatic involvement, whose response to the control of the crises was good due to the introduction - in association with other drugs - of a new anti-epileptic drug, perampanel, a non-competitive antagonist, selective of AMPA-type iono-tropic glutamate receptors on the postsynaptic neurons. The crises decreased from 10-20 per day to 1-2 per month.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Per l'acquisto del singolo articolo scrivi a
abbonamenti@medicoebambino.com
(la mail si prepara da sola con gli estremi dell'articolo);
se accedi, la richiesta parte con un click.
Parole chiave
Classificazione MeSH
Bibliografia di riferimento
La sindrome di Alpers-Huttenlocher
- Finsterer J, Zarrouk Mahjoub S. Epilepsy in mitochondrial disorders. Seizure 2012;21(5):316-21.
- Gordon N. Alpers syndrome: progressive neuronal degeneration of children with liver disease. Dev Med Child Neurol 2006;48(12):1001-3.
- Nurminen A, Farnum GA, Kaguni LS. Pathogenicity in POLG syndromes: DNA polymerase gamma pathogenicity prediction server and database. BBA Clin 2017;7:147-56.
- Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol 2013;48(3):167-78.
- Saneto RP. Alpers-Huttenlocher syndrome: the role of a multidisciplinary health care team. J Multidiscip Healthc 2016;9:323-33.
Perampanel
- Biró A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics 2015;46(2):110-6.
- Commissione Regionale del Farmaco della Regione Emilia-Romagna. Scheda di valutazione del farmaco: Perampanel. DOC PTR n. 276. Approvato 21 gennaio 2016.
- De Liso P, Moavero R, Coppola G, et al. Current role of perampanel in pediatric epilepsy. Ital J Pediatr 2017;43(1):51.
- Heyman E, Lahat E, Levin N, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol 2017;59(4):441-4.
- Ko D, Ramsay RE. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;(197):36-43.
- Rohracher A, Höfler J, Kalss G, et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav 2015;49:354-8.
- Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 2015;8(6):733-40.
- Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E. The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol 2013;20(8):1204-11.